Abstract
The mortality of Coronavirus disease 2019 (COVID-19) appears to be driven by acute respiratory distress syndrome (ARDS) and a dysregulated immune response to SARS-CoV-2. Emerging evidence suggests that a subset of COVID-19 is characterized by the development of a cytokine storm syndrome (CSS), and interleukin (IL)-6 levels are predictors of COVID-19 severity and in-hospital mortality. Targeting hyper-inflammation in COVID-19 may be critical for reducing mortality.
Catecholamines enhance inflammatory injury by augmenting the production of IL-6 and other cytokines through a self-amplifying feed-forward loop in immune cells that requires alpha-1 adrenergic receptor (α1-AR) signaling. Prophylactic inhibition of catecholamine synthesis with the α1-AR antagonist prazosin reduced catecholamines and cytokine responses in mice, and resulted in markedly increased survival following various hyper-inflammatory stimuli. These findings offer a rationale for studying α1-AR antagonists in the prophylaxis of patients with COVID-19-CSS and ARDS.
As high infection rates threaten to overwhelm hospital capacity during this pandemic, preventative approaches that ameliorate COVID-19 severity and reduce excessive mortality are desperately needed. We hypothesize that treatment with prazosin of individuals who test positive for SARS-CoV-2 could reduce catecholamine surges, secondary cytokine dysregulation, and mortality.
To investigate a potential role for α1-AR antagonists in preventing poor outcomes in ARDS, we conducted a retrospective analysis of hospitalized patients diagnosed with ARDS. Using data from the Truven Health MarketScan Research Database (2010-2017), we identified 12,673 men (age 45-64) with ARDS, of whom 1,189 patients (9.4%) were prescribed α1-AR antagonists in the previous year. Applying logistic regression models, we found that patients with prior use of α1-AR antagonists had lower odds of the composite of need for invasive mechanical ventilation and mortality compared to non-users (AOR 0.80, 95% CI 0.69-0.94, p=0.008). Mirroring findings from pre-clinical models, these data support a clinical rationale to study α1-AR antagonists in the prophylaxis of ARDS and states of local and systemic immune dysregulation.
Prospective, randomized clinical trials of alpha-1 receptor antagonists (e.g. prazosin) administered prior to the onset of severe symptoms are needed to assess their efficacy in preventing CSS and reducing mortality in COVID-19.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) encompasses a phylogenetically defined group of evolving viral strains that have caused an ongoing pandemic. Coronavirus disease 2019 (COVID-19) refers to the clinical syndrome of SARS-CoV-2 infection which disproportionally affects older adults with underlying hypertension and heart disease1. The mortality of severe COVID-19 appears to be driven by acute respiratory distress syndrome (ARDS) and a dysregulated immune response to SARS-CoV-22–4.
Emerging evidence suggests that a subset of COVID-19 is characterized by the development of a cytokine storm syndrome (CSS) that resembles cytokine release syndrome (CRS) in chimeric antigen receptor (CAR)-T cell therapy2,4,5. Hyper-inflammation in COVID-19 is associated with elevation of pro-inflammatory cytokines including interleukin (IL)-6, IL-2R, IL-8, tumor necrosis factor-α, and granulocyte-colony stimulating factor4,6. This is similar to the exuberant cytokine production by lung-infiltrating monocytes/macrophages and pneumocytes observed in SARS-CoV and MERS-CoV infection7.
Targeting the hyper-inflammation in COVID-19 may be critical for reducing mortality. IL-6 levels diverge profoundly between non-survivors and survivors in the third week after symptom onset and are predictors of COVID-19 severity and in-hospital mortality1,8,9. Tocilizumab, a monoclonal antibody targeting the IL-6 receptor, is currently being investigated for the treatment of patients with COVID-19-CSS (ChiCTR2000029765, NCT04306705, NCT04310228)10–12. Pending data from randomized controlled trials, retrospective data from 21 patients with severe or critical COVID-19 treated with tocilizumab suggests that inhibition of the IL-6 signaling axis is highly effective13. However, given the cost, immunosuppression, and potential adverse reactions of tocilizumab, this strategy will likely be restricted to select patients in developed countries.
We have recently shown that CRS observed with bacterial infections, CAR-T cells, and other T cell-activating therapies is accompanied by a surge in catecholamines14. Catecholamines enhance inflammatory injury by augmenting the production of IL-6 and other cytokines through a self-amplifying feed-forward loop in immune cells that requires alpha-1 adrenergic receptor (α1-AR) signaling14. Prophylactic inhibition of catecholamine synthesis with metyrosine, a tyrosine hydroxylase antagonist, reduced levels of catecholamines and cytokine responses and resulted in markedly increased survival following various inflammatory stimuli in mice. Similar protection against a hyper-inflammatory stimulus was observed with prazosin, demonstrating that α1-AR antagonists can also prevent cytokine storm14.
To date, no controlled trials have examined the benefits of α1-AR antagonism for the prevention of CSS and ARDS in human subjects. To investigate a potential role for α1-AR antagonists in preventing poor outcomes in ARDS, we conducted a retrospective analysis of hospitalized patients diagnosed with ARDS. Using data from the Truven Health MarketScan Research Database (2010-2017), we identified 12,673 men (age 45-64) with “ARDS” as identified using International Classification of Diseases (ICD)-9 and ICD-10 diagnosis codes. Of these, 1,189 patients (9.4%) were prescribed α1-AR antagonists in the previous year, 8.1% died in the hospital, and 15.6% received invasive mechanical ventilation. Logistic regression models were used to estimate adjusted odds ratios (AOR) and confidence intervals (CI) correlating receipt of α1-AR antagonists (doxazosin, prazosin, silodosin, terazosin, and tamsulosin) in the previous year with these outcomes. Models were adjusted for comorbid conditions in the prior year as well as age and year of hospital admission.
We found that patients with prior use of α1-AR antagonists had lower adjusted odds of the composite of invasive mechanical ventilation and mortality compared to non-users (AOR 0.80, 95% CI 0.69-0.94, p=0.008) (Figure 1). The unadjusted association was similar in magnitude (OR 0.80, 95% CI 0.68-0.94, p=0.007), as were results analyzing each component endpoint separately. Mirroring findings from pre-clinical models, these findings support a clinical rationale to study α1-AR antagonists in the prophylaxis of ARDS and states of local and systemic immune dysregulation. Given the limitations of claims databases and retrospective analyses, our data on their own cannot establish causality or a therapeutic benefit of α1-AR antagonists.
Logistic regression of the composite of invasive mechanical ventilation and in-hospital mortality in patients with ARDS who are on α1-AR antagonists using data from MarketScan Research Database. *adjusted for comorbid hypertension, ischemic heart disease, acute myocardial infarction, heart failure, chronic obstructive pulmonary disease, diabetes mellitus, benign prostatic hyperplasia, and post-traumatic stress disorder identified from health care encounters in the prior year as well as age and year.
The findings discussed herein offer a rationale for studying α1-AR antagonists in the prophylaxis of COVID-19-CSS. However, all drugs can have unanticipated side effects, and the incompletely understood relationship between hypertension and COVID-19 suggests caution in using any agent that impacts blood pressure15. Prospective, double-blinded clinical trials of α1-AR antagonists in high-risk patients, when administered prior to symptom onset, will therefore be required to assess their utility in preventing COVID-19-CSS. Prazosin is inexpensive and safe, as has been documented by long-term treatment of millions of patients with benign prostatic hyperplasia, hypertension, and other conditions. We emphasize that the extensive experience with using prazosin for other indications should prioritize - not obviate - rigorous, controlled clinical research rather than indiscriminate off-label use in patients exposed to SARS-CoV-2. Such trials could be expeditiously implemented in areas suffering from high infection rates that threaten to overwhelm hospital capacity. We encourage readers to recommend specific populations and trial designs to test the hypothesis proposed herein.
Data Availability
NA
Acknowledgements
We thank Adam Sacarny (Columbia University) for advice in processing and analyzing health care claims data. Dr. Sacarny was not compensated for his assistance. This study used the MarketScan Research Databases.
